Supplementary material

Goldie C et al, Niacin therapy and the risk of new-onset diabetes: a meta-analysis of randomised controlled trials

eFigure 1. Data request sheet for niacin trials (page 2)

eFigure 2. Funnel plot of the eleven trials with 95% confidence intervals (page 3)

eFigure 3. Sensitivity analysis on trials that did/ did not use laropiprant (page 4)

eFigure 4. Sensitivity analysis on trials that did/ did not use background statin therapy (page 5)

eFigure 1. Data request sheet for niacin trials

From David Preiss
University of Glasgow

Data request for niacin incident diabetes meta-analysis:

Thank you for approving our request to join this meta-analysis. The following is a summary of the data required to enable us to incorporate data from your trial into the meta-analysis. We do not require all data; the most important is for the numbers developing diabetes. Some studies have access to all three methods to diagnose diabetes and some to only one of the three; this is not problematic and will be highlighted in the resulting manuscript.

Essential data

1. Total number of non-DM subjects at baseline:
    a. Niacin:
    b. Placebo:

2. Methods of diagnosis of diabetes – which of the following were available? (please state *yes / no* as appropriate)
    a. Physician reported (i.e adverse event report): ___
    b. Commencement of oral diabetes medication or insulin: ___
    c. Two elevated fasting plasma glucose values (≥126mg/dL or 7.0mmol/L): ___

3. Number developing diabetes in each group:
    a. Niacin: ___
    b. Placebo: ___

Additional data

4. Age (mean) of all non-DM participants at baseline: ___

5. BMI (mean) of all non-DM participants at baseline: ___

6. Follow up duration (mean): ___

eFigure 2. Funnel plot of the eleven trials with 95% confidence intervals



eFigure 3. Sensitivity analysis on trials that did/ did not use laropiprant



eFigure 4. Sensitivity analysis on trials that did/ did not use background statin therapy